Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


States Reap Rewards From Solo Suits Against Pharma; Atypical Antipsychotics May Offer Test Cases

Executive Summary

First the federal government came knocking at their doors and then state attorneys general followed with claims of health care fraud. Now drug makers are dealing with another nemesis: states that file individual suits instead of joining multistate settlements.

Related Content

PhRMA Fears 'Potentially Limitless' State Suits After Risperdal Case
J&J Challenges Risperdal Penalty As First Amendment Violation
Pharma v. State AGs: GlaxoSmithKline Is Fifth Firm To Challenge Hiring Of Private Counsel
J&J Says Penalties In Arkansas Risperdal Case ‘Excessive,’ Seeks New Trial
Risperdal Jury “Blown Away” By Testimony On Study Manipulation; J&J Settles Texas Suit
States v. Pharma: Atypical Antipsychotics In The Crosshairs
States v. Pharma: Atypical Antipsychotics In The Crosshairs
AstraZeneca Hit With New Compliance Mandates In Seroquel Settlement With States
J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award
Lilly $1.4B Zyprexa Settlement Is Biggest Ever, But Some State Claims Still Pending





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts